8,428 results on '"Fonarow, Gregg C"'
Search Results
2. New models for heart failure care delivery
- Author
-
Xia, Jeffrey, Brownell, Nicholas K, Fonarow, Gregg C, and Ziaeian, Boback
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Clinical Research ,Health Services ,Heart Disease ,Cardiovascular ,Good Health and Well Being ,Humans ,Heart Failure ,Inpatients ,Dashboard Systems ,Minority Groups ,Delivery of Health Care ,Stroke Volume ,Discharge ,Guideline directed medical therapy ,Heart failure ,Implementation ,Inpatient ,Outpatient ,Cardiorespiratory Medicine and Haematology ,Cardiovascular System & Hematology ,Cardiovascular medicine and haematology - Abstract
Heart failure (HF) is a common disease with increasing prevalence around the world. There is high morbidity and mortality associated with poorly controlled HF along with increasing costs and strain on healthcare systems due to a high rate of rehospitalization and resource utilization. Despite the establishment of clear evidence-based guideline directed medical therapies (GDMT) proven to improve HF morbidity and mortality, there remains significant clinical inertia to optimizing HF patients on GDMT. Only a minority of HF patients are prescribed on all four classes of GDMT. To bridge the gap between the vulnerable population of HF patients and lifesaving GDMT, HF implementation is of increasing importance. HF implementation involves strategies and techniques to improve GDMT optimization along with other modalities to improve HF management. HF implementation meets patients where they are, including at the time of acute decompensation in the inpatient setting, at the vulnerable discharge stage, and at the chronic management stage in the outpatient setting. Inpatient HF implementation strategies include protocolized rapid titration of GDMT, site-level audit-and-feedback, virtual GDMT optimization teams, and electronic health record notifications and alerts. Discharge HF implementation strategies include education at patient and provider levels, discharge summaries, and HF transitional programs. Outpatient HF implementation strategies include digital innovations such as electronic health record utilization and mobile applications, population level strategies such as registries and clinical dashboards), changes in HF team structure and member roles, remote monitoring with implanted devices and telemonitoring, and hospital at home care model. With a growing population of HF patients, there is an increasing need for novel and creative HF implementation and monitoring methods.
- Published
- 2024
3. Economic Modeling Analysis of an Intensive GDMT Optimization Program in Hospitalized Heart Failure Patients
- Author
-
Dixit, Neal M, Parikh, Neil U, Ziaeian, Boback, and Fonarow, Gregg C
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Trials and Supportive Activities ,Comparative Effectiveness Research ,Patient Safety ,Heart Disease ,Cardiovascular ,Clinical Research ,Health Services ,Cost Effectiveness Research ,Good Health and Well Being ,Humans ,Heart Failure ,Stroke Volume ,Hospitalization ,cost-effectiveness analysis ,heart failure ,humans ,outpatients ,patient readmission ,Biochemistry and Cell Biology ,Cardiorespiratory Medicine and Haematology ,Medical Physiology ,Cardiovascular System & Hematology ,Cardiovascular medicine and haematology ,Medical physiology - Abstract
Background: The STRONG-HF trial demonstrated substantial reductions in the composite of mortality and morbidity over 6 months among hospitalized heart failure patients who were randomized to intensive guideline-directed medical therapy (GDMT) optimization compared to usual care. Whether an intensive GDMT optimization program would be cost-effective for patients with heart failure with reduced ejection fraction (HFrEF) is unknown. Methods: Using a 2-state Markov model we evaluated the effect of an intensive GDMT optimization program on hospitalized patients with HFrEF. Two population models were created to simulate this intervention, a "Clinical Trial" model, based off the participants in the STRONG-HF trial and a "Real-World" model, based off the Get With The Guidelines-HF Registry of patients admitted with worsening HF. We then modeled the effect of a 6-month intensive triple therapy GDMT optimization program comprised of cardiologists, clinical pharmacists, and registered nurses. Hazard ratios from the intervention arm of the STRONG-HF trial were applied to both populations models to simulate clinical and financial outcomes of an intensive GDMT optimization program from a United States healthcare sector perspective with a lifetime time horizon. Optimal quadruple GDMT use was also modeled. Results: An intensive GDMT optimization program was extremely cost-effective with incremental cost-effectiveness ratios
- Published
- 2023
4. Impact of Age and Variant Time Period on Clinical Presentation and Outcomes of Hospitalized Coronavirus Disease 2019 Patients.
- Author
-
Srivastava, Pratyaksh K, Klomhaus, Alexandra M, Tehrani, David M, Fonarow, Gregg C, Ziaeian, Boback, Desai, Pooja S, Rafique, Asim, de Lemos, James, Parikh, Rushi V, and Yang, Eric H
- Abstract
To evaluate the impact of age and COVID-19 variant time period on morbidity and mortality among those hospitalized with COVID-19.Patients from the American Heart Association's Get With The Guidelines COVID-19 cardiovascular disease registry (January 20, 2020-February 14, 2022) were divided into groups based on whether they presented during periods of wild type/alpha, delta, or omicron predominance. They were further subdivided by age (young: 18-40 years; older: more than 40 years), and characteristics and outcomes were compared.The cohort consisted of 45,421 hospitalized COVID-19 patients (wild type/alpha period: 41,426, delta period: 3349, and omicron period: 646). Among young patients (18-40 years), presentation during delta was associated with increased odds of severe COVID-19 (OR, 1.6; 95% CI, 1.3-2.1), major adverse cardiovascular events (MACE) (OR, 1.8; 95% CI, 1.3-2.5), and in-hospital mortality (OR, 2.2; 95% CI, 1.5-3.3) when compared with presentation during wild type/alpha. Among older patients (more than 40 years), presentation during delta was associated with increased odds of severe COVID-19 (OR, 1.2; 95% CI, 1.1-1.3), MACE (OR, 1.5; 95% CI, 1.4-1.7), and in-hospital mortality (OR, 1.4; 95% CI, 1.3-1.6) when compared with wild type/alpha. Among older patients (more than 40 years), presentation during omicron associated with decreased odds of severe COVID-19 (OR, 0.7; 95% CI, 0.5-0.9) and in-hospital mortality (OR, 0.6; 95% CI, 0.5-0.9) when compared with wild type/alpha.Among hospitalized adults with COVID-19, presentation during a time of delta predominance was associated with increased odds of severe COVID-19, MACE, and in-hospital mortality compared with presentation during wild type/alpha. Among older patients (aged more than 40 years), presentation during omicron was associated with decreased odds of severe COVID-19 and in-hospital mortality compared with wild type/alpha.
- Published
- 2023
5. Heart Failure Epidemiology and Outcomes Statistics: A Report of the Heart Failure Society of America
- Author
-
Bozkurt, Biykem, Ahmad, Tariq, Alexander, Kevin M, Baker, William L, Bosak, Kelly, Breathett, Khadijah, Fonarow, Gregg C, Heidenreich, Paul, Ho, Jennifer E, Hsich, Eileen, Ibrahim, Nasrien E, Jones, Lenette M, Khan, Sadiya S, Khazanie, Prateeti, Koelling, Todd, Krumholz, Harlan M, Khush, Kiran K, Lee, Christopher, Morris, Alanna A, Page, Robert L, Pandey, Ambarish, Piano, Mariann R, Stehlik, Josef, Stevenson, Lynne Warner, Teerlink, John R, Vaduganathan, Muthiah, Ziaeian, Boback, and Members, Writing Committee
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Clinical Sciences ,Humans ,Heart Failure ,Hospitalization ,Prevalence ,Incidence ,Writing Committee Members ,Heart failure ,epidemiology ,incidence ,mortality ,outcomes ,prevalence ,Cardiorespiratory Medicine and Haematology ,Nursing ,Cardiovascular System & Hematology ,Cardiovascular medicine and haematology ,Clinical sciences - Published
- 2023
6. Geographic Variation in the Quality of Heart Failure Care Among U.S. Veterans.
- Author
-
Kosaraju, Revanth S, Fonarow, Gregg C, Ong, Michael K, Heidenreich, Paul A, Washington, Donna L, Wang, Xiaoyan, and Ziaeian, Boback
- Subjects
Veterans Affairs ,differences ,guideline-directed medical therapies ,heart failure ,map ,national ,Heart Disease ,Cardiovascular ,Cardiorespiratory Medicine and Haematology - Abstract
BackgroundThe burden of heart failure is growing. Guideline-directed medical therapies (GDMT) reduce adverse outcomes in heart failure with reduced ejection fraction (HFrEF). Whether there is geographic variation in HFrEF quality of care is not well described.ObjectivesThis study evaluated variation nationally for prescription of GDMT within the Veterans Health Administration.MethodsA cohort of Veterans with HFrEF had their address linked to hospital referral regions (HRRs). GDMT prescription was defined using pharmacy data between July 1, 2020, and July 1, 2021. Within HRRs, we calculated the percentage of Veterans prescribed GDMT and a composite GDMT z-score. National choropleth maps were created to evaluate prescription variation. Associations between GDMT performance and demographic characteristics were evaluated using linear regression.ResultsMaps demonstrated significant variation in the HRR composite score and GDMT prescriptions. Within HRRs, the prescription of beta-blockers to Veterans was highest with a median of 80% (IQR: 77.3%-82.2%) followed by angiotensin-converting enzyme inhibitor/angiotensin receptor blocker/angiotensin receptor-neprilysin inhibitors (69.3%; IQR: 66.4%-72.1%), sodium-glucose cotransporter 2 inhibitors (10.3%; IQR: 7.7%-12.8%), mineralocorticoid receptor antagonists (29.2%; IQR: 25.8%-33.9%), and angiotensin receptor-neprilysin inhibitors (12.2%; IQR: 8.6%-15.3%). HRR composite GDMT z-scores were inversely associated with the HRR median Gini coefficient (R = -0.13; P = 0.0218) and the percentage of low-income residents (R = -0.117; P = 0.0413).ConclusionsWide geographic differences exist for HFrEF care. Targeted strategies may be required to increase GDMT prescription for Veterans in lower-performing regions, including those affected by income inequality and poverty.
- Published
- 2023
7. DASH-HF Study: A Pragmatic Quality Improvement Randomized Implementation Trial for Patients With Heart Failure With Reduced Ejection Fraction.
- Author
-
Verma, Aradhana, Fonarow, Gregg C, Hsu, Jeffrey J, Jackevicius, Cynthia A, Vaghaiwalla Mody, Freny, Nguyen, Amanda, Amidi, Omid, Goldberg, Sarah, Vetrivel, Reeta, Upparapalli, Deepti, Theodoropoulos, Kleanthis, Gregorio, Stephanie, Chang, Donald S, Bostrom, Kristina, Althouse, Andrew D, and Ziaeian, Boback
- Subjects
guideline-directed medical therapy ,heart failure with reduced ejection fraction ,medications ,quality improvement ,telehealth ,Comparative Effectiveness Research ,Prevention ,Health Services ,Clinical Trials and Supportive Activities ,Clinical Research ,Heart Disease ,Cardiovascular ,Good Health and Well Being ,Biochemistry and Cell Biology ,Cardiorespiratory Medicine and Haematology ,Medical Physiology ,Cardiovascular System & Hematology - Abstract
BackgroundHeart failure is a prevailing diagnosis of hospitalization and readmission within 6 months, and nearly a quarter of these patients die within a year. Guideline-directed medication therapies reduce risk of mortality by 73% over 2 years; however, the implementation of these therapies to their target dose in clinical practice continues to be challenging. In 2020, the Veterans Affairs (VA) Health Care System developed a HF dashboard to monitor and improve outpatient HF management. The DASH-HF (Dashboard Activated Services and Telehealth for Heart Failure) study is a randomized, pragmatic clinical trial to evaluate proactive dashboard-directed telehealth clinics to improve the use and dosing of guideline-directed medication therapy for patients with heart failure with reduced ejection fraction not on optimal guideline-directed medication therapy within the VA.MethodsThree hundred veterans with heart failure with reduced ejection fraction met inclusion criteria with an optimization potential score (OPS) of 5 or less out of 10, representing nonoptimal guideline-directed medication therapy. The primary outcome was a composite score of guideline-directed medical therapy, the OPS, 6 months after the end of the intervention. Secondary outcomes included active prescriptions for each individual guideline-directed medical therapy class, HF-related hospitalizations, deaths, and clinician time per patient during the intervention clinics.ResultsThere was no significant difference between the intervention arm and usual care group in the primary outcome (OPS, 2.9; SD=2.1 versus OPS, 2.6, SD=2.1); adjusted mean difference 0.3 (95% CI, -0.1 to 0.7) or in the prespecified secondary outcomes for hospitalization and all-cause mortality for the intervention of proactive dashboard-based clinics.ConclusionsA dashboard-based clinic intervention did not improve the OPS or secondary outcomes of hospitalization and all-cause mortality. There remains a larger opportunity to better target patients and provide more intensive follow-up to further evaluate the utility of proactive dashboard-based clinics for HF management and quality improvement.RegistrationURL: https://www.Clinicaltrialsgov; Unique identifier: NCT05001165.
- Published
- 2023
8. Optimizing Guideline-directed Medical Therapies for Heart Failure with Reduced Ejection Fraction During Hospitalization
- Author
-
Dixit, Neal M, Shah, Shivani, Ziaeian, Boback, Fonarow, Gregg C, and Hsu, Jeffrey J
- Subjects
Heart Disease ,Clinical Research ,Cardiovascular ,5.1 Pharmaceuticals ,Development of treatments and therapeutic interventions ,Good Health and Well Being - Abstract
Heart failure remains a huge societal concern despite medical advancement, with an annual direct cost of over $30 billion. While guideline-directed medical therapy (GDMT) is proven to reduce morbidity and mortality, many eligible patients with heart failure with reduced ejection fraction (HFrEF) are not receiving one or more of the recommended medications, often due to suboptimal initiation and titration in the outpatient setting. Hospitalization serves as a key point to initiate and titrate GDMT. Four evidence-based therapies have clinical benefit within 30 days of initiation and form a crucial foundation for HFrEF therapy: renin-angiotensin-aldosterone system inhibitors with or without a neprilysin inhibitor, β-blockers, mineralocorticoid-receptor-antagonists, and sodium-glucose cotransporter-2 inhibitors. The authors present a practical guide for the implementation of these four pillars of GDMT during a hospitalization for acute heart failure.
- Published
- 2023
9. Blood Pressure Variability and Risk of Atrial Fibrillation in Adults With Type 2 Diabetes.
- Author
-
Kaze, Arnaud D, Yuyun, Matthew F, Fonarow, Gregg C, and Echouffo-Tcheugui, Justin B
- Subjects
atrial fibrillation ,blood pressure ,diabetes type 2 ,epidemiology ,Diabetes ,Prevention ,Clinical Research ,Heart Disease ,Cardiovascular - Abstract
BackgroundThere is a paucity of epidemiological data on the association between long-term variability of blood pressure (BP) and incident atrial fibrillation (AF).ObjectivesThe purpose of this study was to evaluate the association of BP variability with incident AF in a large sample of adults with type 2 diabetes.MethodsWe included participants who had ≥5 BP measurements in the first 24 months of action to control cardiovascular risk in diabetes. The visit-to-visit variability of systolic blood pressure (SBP) and diastolic blood pressure (DBP) was estimated using the coefficient of variation, SD, and variability independent of the mean. Incident AF was recorded using follow-up electrocardiograms. Modified Poisson regression was used to generate risk ratios (RRs) and 95% CI for AF.ResultsA total of 8,399 participants were included (average age 62.6 ± 6.5 years, 38.8% women, 63.2% White). Over a median follow-up of 5 years, 155 developed AF. Compared to the lowest quartile, the highest quartile of BP variability was associated with an increased risk of AF (RR: 1.85 [95% CI: 1.13-3.03] and 1.63 [95% CI: 1.01-2.65] for coefficient of variation of SBP and DBP, respectively). Participants in the highest quartile of both SBP and DBP had a 2-fold higher risk of AF compared to those in the lowest 3 quartiles of both SBP and DBP (RR: 1.94; 95% CI: 1.29-2.93).ConclusionsIn a large cohort of adults with type 2 diabetes, higher variability in SBP and DBP was independently associated with an increased risk of AF.
- Published
- 2023
10. Clinical Profile, Health Care Costs, and Outcomes of Patients Hospitalized for Heart Failure With Severely Reduced Ejection Fraction
- Author
-
Harrington, Josephine, Sun, Jie‐Lena, Fonarow, Gregg C, Heitner, Stephen B, Divanji, Punag H, Binder, Gary, Allen, Larry A, Alhanti, Brooke, Yancy, Clyde W, Albert, Nancy M, DeVore, Adam D, Felker, G Michael, and Greene, Stephen J
- Subjects
Cardiovascular ,Heart Disease ,Clinical Research ,Humans ,Aged ,United States ,Stroke Volume ,Aftercare ,Patient Discharge ,Medicare ,Heart Failure ,Hospitalization ,Health Care Costs ,costs ,ejection fraction ,heart failure ,outcomes ,Cardiorespiratory Medicine and Haematology - Abstract
Background Many patients with heart failure (HF) have severely reduced ejection fraction but do not meet threshold for consideration of advanced therapies (ie, stage D HF). The clinical profile and health care costs associated with these patients in US practice is not well described. Methods and Results We examined patients hospitalized for worsening chronic heart failure with reduced ejection fraction ≤40% from 2014 to 2019 in the GWTG-HF (Get With The Guidelines-Heart Failure) registry, who did not receive advanced HF therapies or have end-stage kidney disease. Patients with severely reduced EF defined as EF ≤30% were compared with those with EF 31% to 40% in terms of clinical profile and guideline-directed medical therapy. Among Medicare beneficiaries, postdischarge outcomes and health care expenditure were compared. Among 113 348 patients with EF ≤40%, 69% (78 589) had an EF ≤30%. Patients with severely reduced EF ≤30% tended to be younger and were more likely to be Black. Patients with EF ≤30% also tended to have fewer comorbidities and were more likely to be prescribed guideline-directed medical therapy ("triple therapy" 28.3% versus 18.2%, P
- Published
- 2023
11. Cost-Effectiveness of Comprehensive Quadruple Therapy for Heart Failure With Reduced Ejection Fraction.
- Author
-
Dixit, Neal M, Parikh, Neil U, Ziaeian, Boback, Jackson, Nicholas, and Fonarow, Gregg C
- Subjects
Humans ,Ventricular Dysfunction ,Left ,Adrenergic beta-Antagonists ,Angiotensin-Converting Enzyme Inhibitors ,Stroke Volume ,Cost-Benefit Analysis ,United States ,Heart Failure ,Angiotensin Receptor Antagonists ,Mineralocorticoid Receptor Antagonists ,Markov model ,cost-effectiveness analysis ,guideline-directed medical therapy ,heart failure with reduced ejection fraction ,high-value care ,incremental cost effectiveness ratio ,Health Services ,Clinical Research ,Comparative Effectiveness Research ,Heart Disease ,Cardiovascular ,Cost Effectiveness Research ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Good Health and Well Being ,Cardiorespiratory Medicine and Haematology - Abstract
BackgroundHeart failure with reduced ejection fraction (HFrEF) is one of the most costly and deadly chronic disease states. The cost effectiveness of a comprehensive quadruple therapy regimen for HFrEF has not been studied.ObjectivesThe authors sought to determine the cost-effectiveness of quadruple therapy comprised of beta-blockers, mineralocorticoid receptor antagonists, angiotensin receptor-neprilysin inhibitors, and sodium glucose cotransporter-2 inhibitors vs regimens composed of only beta-blockers, angiotensin-converting enzyme inhibitors, and mineralocorticoid receptor antagonists (triple therapy), and angiotensin-converting enzyme inhibitors and beta-blockers (double therapy).MethodsUsing a 2-state Markov model, the authors performed a cost-effectiveness study using simulated populations of 1,000 patients with HFrEF based on the participants in the PARADIGM-HF (Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure) trial and compared them by treatment strategy (quadruple therapy vs triple and double therapy) from a United States health care system perspective. The authors also performed 10,000 probabilistic simulations.ResultsTreatment with quadruple therapy resulted in an increase of 1.73 and 2.87 life-years compared with triple therapy and double therapy, respectively, and an increase in quality-adjusted life-years of 1.12 and 1.85 years, respectively. The incremental cost-effectiveness ratios of quadruple therapy vs triple therapy and double therapy were $81,000 and $51,081, respectively. In 91.7% and 99.9% of probabilistic simulations quadruple therapy had an incremental cost-effectiveness ratio of
- Published
- 2023
12. SGLT2 Inhibitors for Heart Failure with Preserved Ejection Fraction: What Hospitalists Need to Know
- Author
-
Greene, Stephen J., Fonarow, Gregg C., and Butler, Javed
- Published
- 2024
- Full Text
- View/download PDF
13. Temporal trends and rural–urban disparities in cerebrovascular risk factors, in-hospital management and outcomes in ischaemic strokes in China from 2005 to 2015: a nationwide serial cross-sectional survey
- Author
-
Wang, Chun-Juan, Gu, Hong-Qiu, Zhang, Xin-Miao, Jiang, Yong, Li, Hao, Bettger, Janet Prvu, Meng, Xia, Dong, Ke-Hui, Wangqin, Run-Qi, Yang, Xin, Wang, Meng, Liu, Chelsea, Liu, Li-Ping, Tang, Bei-Sha, Li, Guo-Zhong, Xu, Yu-Ming, He, Zhi-Yi, Yang, Yi, Yip, Winnie, Fonarow, Gregg C, Schwamm, Lee H, Xian, Ying, Zhao, Xing-Quan, Wang, Yi-Long, Wang, Yongjun, and Li, Zixiao
- Subjects
Health Services and Systems ,Biomedical and Clinical Sciences ,Health Sciences ,Neurosciences ,Prevention ,Clinical Research ,Brain Disorders ,Stroke ,Cardiovascular ,Good Health and Well Being ,Humans ,Cross-Sectional Studies ,Brain Ischemia ,Risk Factors ,Ischemic Stroke ,Hospitals ,Urban - Abstract
BackgroundStroke is the leading cause of mortality in China, with limited evidence of in-hospital burden obtained from nationwide surveys. We aimed to monitor and track the temporal trends and rural-urban disparities in cerebrovascular risk factors, management and outcomes from 2005 to 2015.MethodsWe used a two-stage random sampling survey to create a nationally representative sample of patients admitted for ischaemic stroke in 2005, 2010 and 2015. We sampled participating hospitals with an economic-geographical region-stratified random-sampling approach first and then obtained patients with a systematic sampling approach. We weighed our survey data to estimate the national-level results and assess changes from 2005 to 2015.ResultsWe analysed 28 277 ischaemic stroke admissions from 189 participating hospitals. From 2005 to 2015, the estimated national hospital admission rate for ischaemic stroke per 100 000 people increased (from 75.9 to 402.7, Ptrend
- Published
- 2023
14. Impact of COVID-19 in patients hospitalized with stress cardiomyopathy: A nationwide analysis
- Author
-
Hajra, Adrija, Malik, Aaqib, Bandyopadhyay, Dhrubajyoti, Goel, Akshay, Isath, Ameesh, Gupta, Rahul, Krishnan, Suraj, Rai, Devesh, Krittanawong, Chayakrit, Virani, Salim S, Fonarow, Gregg C, and Lavie, Carl J
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Infectious Diseases ,Hematology ,Kidney Disease ,Infection ,Renal and urogenital ,Good Health and Well Being ,Humans ,Female ,COVID-19 ,Hospitalization ,Shock ,Cardiogenic ,Inpatients ,Acute Kidney Injury ,Retrospective Studies ,Acute coronary syndrome ,Congestive heart failure ,Covid ,Stress cardiomyopathy ,Cardiorespiratory Medicine and Haematology ,Cardiovascular System & Hematology ,Cardiovascular medicine and haematology - Abstract
Stress cardiomyopathy was noted to occur at a higher incidence during coronavirus disease of 2019 (COVID-19) pandemic. This database analysis has been done to compare the in-hospital outcomes in patients with stress cardiomyopathy and concurrent COVID-19 infection with those without COVID-19 infection. The National Inpatient Sample database for the year 2020 was queried to identify all admissions diagnosed with stress cardiomyopathy. These patients were then stratified based on whether they had concomitant COVID-19 infection or not. A 1:1 propensity score matching was performed. Multivariate logistic regression analysis was done to identify predictors of mortality. We identified 41,290 hospitalizations for stress cardiomyopathy, including 1665 patients with concurrent diagnosis of COVID-19. The female preponderance was significantly lower in patients with stress cardiomyopathy and COVID-19. Patients with concomitant COVID-19 were more likely to be African American, diabetic and have chronic kidney disease. After propensity matching, the incidence of complications, including acute kidney injury (AKI), AKI requiring dialysis, coagulopathy, sepsis, cardiogenic shock, cases with prolonged intubation of >24 h, requirement of vasopressor and inpatient mortality, were noted to be significantly higher in patients with COVID-19. Concomitant COVID-19 infection was independently associated with worse outcomes and increased mortality in patients hospitalized with stress cardiomyopathy.
- Published
- 2023
15. Characteristics, Treatment Patterns, and Clinical Outcomes After Heart Failure Hospitalizations During the COVID-19 Pandemic, March to October 2020
- Author
-
Yousufuddin, Mohammed, Yamani, Mohamad H, Kashani, Kianoush B, Zhu, Ye, Wang, Zhen, Seshadri, Ashok, Blocker, Katherine R, Peters, Jessica L, Doss, Jewell M, Karam, Dhauna, Khandelwal, Kanika, Sharma, Umesh M, Dudenkov, Daniel V, Mehmood, Tahir, Pagali, Sandeep R, Nanda, Sanjeev, Abdalrhim, Ahmed D, Cummings, Nichole, Dugani, Sagar B, Smerina, Michael, Prokop, Larry J, Keenan, Lawrence R, Bhagra, Sumit, Jahangir, Arshad, Bauer, Philippe R, Fonarow, Gregg C, and Murad, Mohammad Hassan
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Cardiovascular ,Heart Disease ,Patient Safety ,2.4 Surveillance and distribution ,Aetiology ,Good Health and Well Being ,Male ,Adult ,Humans ,Aged ,Pandemics ,Cohort Studies ,COVID-19 ,Hospitalization ,Patient Readmission ,Heart Failure ,Medical and Health Sciences ,Biomedical and clinical sciences - Abstract
ObjectiveTo compare clinical characteristics, treatment patterns, and 30-day all-cause readmission and mortality between patients hospitalized for heart failure (HF) before and during the coronavirus disease 2019 (COVID-19) pandemic.Patients and methodsThe study was conducted at 16 hospitals across 3 geographically dispersed US states. The study included 6769 adults (mean age, 74 years; 56% [5033 of 8989] men) with cumulative 8989 HF hospitalizations: 2341 hospitalizations during the COVID-19 pandemic (March 1 through October 30, 2020) and 6648 in the pre-COVID-19 (October 1, 2018, through February 28, 2020) comparator group. We used Poisson regression, Kaplan-Meier estimates, multivariable logistic, and Cox regression analysis to determine whether prespecified study outcomes varied by time frames.ResultsThe adjusted 30-day readmission rate decreased from 13.1% (872 of 6648) in the pre-COVID-19 period to 10.0% (234 of 2341) in the COVID-19 pandemic period (relative risk reduction, 23%; hazard ratio, 0.77; 95% CI, 0.66 to 0.89). Conversely, all-cause mortality increased from 9.7% (645 of 6648) in the pre-COVID-19 period to 11.3% (264 of 2341) in the COVID-19 pandemic period (relative risk increase, 16%; number of admissions needed for one additional death, 62.5; hazard ratio, 1.19; 95% CI, 1.02 to 1.39). Despite significant differences in rates of index hospitalization, readmission, and mortality across the study time frames, the disease severity, HF subtypes, and treatment patterns remained unchanged (P>0.05).ConclusionThe findings of this large tristate multicenter cohort study of HF hospitalizations suggest lower rates of index hospitalizations and 30-day readmissions but higher incidence of 30-day mortality with broadly similar use of HF medication, surgical interventions, and devices during the COVID-19 pandemic compared with the pre-COVID-19 time frame.
- Published
- 2023
16. Sex Differences in Outcomes of Percutaneous Pulmonary Artery Thrombectomy in Patients With Pulmonary Embolism.
- Author
-
Agarwal, Manyoo A, Dhaliwal, Jasmeet S, Yang, Eric H, Aksoy, Olcay, Press, Marcella, Watson, Karol, Ziaeian, Boback, Fonarow, Gregg C, Moriarty, John M, Saggar, Rajan, and Channick, Richard
- Subjects
Pulmonary Artery ,Humans ,Pulmonary Embolism ,Treatment Outcome ,Thrombectomy ,Retrospective Studies ,Cross-Sectional Studies ,Sex Characteristics ,United States ,Female ,Male ,disparities ,hospitalizations ,outcomes ,pulmonary embolism ,sex ,sex differences ,thrombectomy ,Lung ,Patient Safety ,Cardiovascular ,Clinical Trials and Supportive Activities ,Clinical Research ,Aging ,Good Health and Well Being ,  ,differences ,Clinical Sciences ,Respiratory System - Abstract
BackgroundThe sex differences in use, safety outcomes, and health-care resource use of patients with pulmonary embolism (PE) undergoing percutaneous pulmonary artery thrombectomy are not well characterized.Research questionWhat are the sex differences in outcomes for patients diagnosed with PE who undergo percutaneous pulmonary artery thrombectomy?Study design and methodsThis retrospective cross-sectional study used national inpatient claims data to identify patients in the United States with a discharge diagnosis of PE who underwent percutaneous thrombectomy between January 2016 and December 2018. We evaluated the demographics, comorbidities, safety outcomes (in-hospital mortality), and health-care resource use (discharge to home, length of stay, and hospital charges) of patients with PE undergoing percutaneous thrombectomy.ResultsAmong 1,128,904 patients with a diagnosis of PE between 2016 and 2018, 5,160 patients (0.5%) underwent percutaneous pulmonary artery thrombectomy. When compared with male patients, female patients showed higher procedural bleeding (16.9% vs 11.2%; P < .05), required more blood transfusions (11.9% vs 5.7%; P < .05), and experienced more vascular complications (5.0% vs 1.5%; P < .05). Women experienced higher in-hospital mortality (16.9% vs 9.3%; adjusted OR, 1.9; 95% CI, 1.2-3.0; P = .003) when compared with men. Although length of stay and hospital charges were similar to those of men, women were less likely to be discharged home after surviving hospitalization (47.9% vs 60.3%; adjusted OR, 0.7; 95% CI, 0.50-0.99; P = .04).InterpretationIn this large nationwide cohort, women with PE who underwent percutaneous thrombectomy showed higher morbidity and in-hospital mortality compared with men.
- Published
- 2023
17. Prevalence and prognostic implications of reduced left ventricular ejection fraction among patients with STEMI in India
- Author
-
Hendrickson, Michael J, Arora, Sameer, Vaduganathan, Muthiah, Fonarow, Gregg C, Mp, Girish, Bansal, Ankit, Batra, Vishal, Kunal, Shekhar, Bhatt, Deepak L, Gupta, Mohit, and Qamar, Arman
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Patient Safety ,Clinical Research ,Prevention ,Good Health and Well Being ,Humans ,ST Elevation Myocardial Infarction ,Prognosis ,Ventricular Function ,Left ,Stroke Volume ,Prevalence ,Angiotensin Receptor Antagonists ,Angiotensin-Converting Enzyme Inhibitors ,NORIN-STEMI ,ST-elevation myocardial infarction ,atherosclerotic cardiovascular disease ,heart failure ,left ventricular dysfunction ,Cardiorespiratory Medicine and Haematology ,Cardiovascular medicine and haematology - Abstract
AimsTo describe clinical characteristics and outcomes for those with STEMI and reduced left ventricular ejection fraction (LVEF) in low-income and middle-income countries (LMICs).Methods and resultsAdults presenting with STEMI to two government-owned tertiary care centres in Delhi, India were prospectively enrolled in the North India ST-elevation myocardial infarction (NORIN-STEMI) registry. LVEF was evaluated at presentation and clinical characteristics were compared across LVEF categories. Overall, 3597 patients were included, of whom 468 (13%) had LVEF >50%, 1482 (41%) had mildly reduced LVEF (40-49%), 1357 (38%) had moderately reduced LVEF (30-39%), and 290 (8%) had severely reduced LVEF (24 h, prior MI, and hyperlipidaemia were associated with decreasing LVEF category. Although most patients with reduced LVEF were discharged on appropriate guideline-directed therapies, adherence at 1 year was low (ACE inhibitor/ARB 91% to 41%, beta blocker 98% to 78%, aldosterone receptor antagonist 69% to 6%). After multivariable adjustment, a Cox regression model showed moderately reduced LVEF (HR 1.77, 95% CI 1.20, 2.60) and severely reduced LVEF (HR 3.63, 95% CI 2.41, 5.48) were associated with increased risk of all-cause mortality compared with LVEF ≥50%.ConclusionsOn presentation for STEMI, almost 90% of NORIN-STEMI participants had at least mildly reduced LVEF and almost half had LVEF
- Published
- 2022
18. Cardiac Rehabilitation and the COVID-19 Pandemic: Persistent Declines in Cardiac Rehabilitation Participation and Access Among US Medicare Beneficiaries.
- Author
-
Varghese, Merilyn S, Beatty, Alexis L, Song, Yang, Xu, Jiaman, Sperling, Laurence S, Fonarow, Gregg C, Keteyian, Steven J, McConeghy, Kevin W, Penko, Joanne, Yeh, Robert W, Figueroa, Jose F, Wu, Wen-Chih, and Kazi, Dhruv S
- Subjects
Humans ,Aged ,Medicaid ,Medicare ,United States ,Pandemics ,Cardiac Rehabilitation ,COVID-19 ,cardiac rehabilitation ,pandemics ,Rehabilitation ,Health Services ,Clinical Research ,Good Health and Well Being ,Cardiorespiratory Medicine and Haematology ,Public Health and Health Services ,Cardiovascular System & Hematology - Abstract
BackgroundThe impact of the COVID-19 pandemic on participation in and availability of cardiac rehabilitation (CR) is unknown.MethodsAmong eligible Medicare fee-for-service beneficiaries, we evaluated, by month, the number of CR sessions attended per 100 000 beneficiaries, individuals eligible to initiate CR, and centers offering in-person CR between January 2019 and December 2021. We compared these outcomes between 2 periods: December 1, 2019 through February 28, 2020 (period 1, before declaration of the pandemic-related national emergency) and October 1, 2021 through December 31, 2021 (period 2, the latest period for which data are currently available).ResultsIn period 1, Medicare beneficiaries participated in (mean±SD) 895±84 CR sessions per 100 000 beneficiaries each month. After the national emergency was declared, CR participation sharply declined to 56 CR sessions per 100 000 beneficiaries in April 2020. CR participation recovered gradually through December 2021 but remained lower than prepandemic levels (period 2: 698±29 CR sessions per month per 100 000 beneficiaries, P=0.02). Declines in CR participation were most marked among dual Medicare and Medicaid enrollees and patients residing in rural areas or socially vulnerable communities. There was no statistically significant change in CR eligibility between the 2 periods. Compared with 2618±5 CR centers in period 1, there were 2464±7 in period 2 (P
- Published
- 2022
19. Variability of adiposity indices and incident heart failure among adults with type 2 diabetes
- Author
-
Kaze, Arnaud D, Erqou, Sebhat, Santhanam, Prasanna, Bertoni, Alain G, Ahima, Rexford S, Fonarow, Gregg C, and Echouffo-Tcheugui, Justin B
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Prevention ,Obesity ,Aging ,Heart Disease ,Diabetes ,Nutrition ,Clinical Research ,Cardiovascular ,Metabolic and endocrine ,Adiposity ,Aged ,Body Mass Index ,Diabetes Mellitus ,Type 2 ,Female ,Heart Disease Risk Factors ,Heart Failure ,Humans ,Incidence ,Male ,Middle Aged ,Predictive Value of Tests ,Prognosis ,Prospective Studies ,Randomized Controlled Trials as Topic ,Risk Assessment ,Time Factors ,United States ,Waist Circumference ,Cardiovascular disease ,Diabetes ,type 2 ,Epidemiology ,Heart failure ,Cardiorespiratory Medicine and Haematology ,Cardiovascular System & Hematology ,Cardiovascular medicine and haematology - Abstract
BackgroundIt remains unclear how the variability of adiposity indices relates to incident HF. This study evaluated the associations of the variability in several adiposity indices with incident heart failure (HF) in individuals with type 2 diabetes (T2DM).MethodsWe included 4073 participants from the Look AHEAD (Action for Health in Diabetes) study. We assessed variability of body mass index (BMI), waist circumference (WC), and body weight across four annual visits using three variability metrics, the variability independent of the mean (VIM), coefficient of variation (CV), and intraindividual standard deviation (SD). Multivariable Cox regression models were used to generate adjusted hazard ratios (aHR) and 95% confidence intervals (CI) for incident HF.ResultsOver a median of 6.7 years, 120 participants developed incident HF. After adjusting for relevant confounders including baseline adiposity levels, the aHR for the highest (Q4) versus lowest quartile (Q1) of VIM of BMI was 3.61 (95% CI 1.91-6.80). The corresponding aHRs for CV and SD of BMI were 2.48 (95% CI 1.36-4.53) and 2.88 (1.52-5.46), respectively. Regarding WC variability, the equivalent aHRs were 1.90 (95% CI 1.11-3.26), 1.79 (95% CI 1.07-3.01), and 1.73 (1.01-2.95) for Q4 versus Q1 of VIM, CV and SD of WC, respectively.ConclusionsIn a large sample of adults with T2DM, a greater variability of adiposity indices was associated with higher risks of incident HF, independently of traditional risk factors and baseline adiposity levels. Registration-URL: https://clinicaltrials.gov/ct2/show/NCT00000620 .
- Published
- 2022
20. Diabetic kidney disease and risk of incident stroke among adults with type 2 diabetes
- Author
-
Kaze, Arnaud D, Jaar, Bernard G, Fonarow, Gregg C, and Echouffo-Tcheugui, Justin B
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Brain Disorders ,Diabetes ,Kidney Disease ,Prevention ,Clinical Research ,Stroke ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Metabolic and endocrine ,Renal and urogenital ,Albuminuria ,Diabetes Mellitus ,Type 2 ,Diabetic Nephropathies ,Female ,Glomerular Filtration Rate ,Humans ,Male ,Middle Aged ,Diabetic kidney disease ,Epidemiology ,Glomerular filtration rate ,Type 2 diabetes ,Medical and Health Sciences ,General & Internal Medicine ,Biomedical and clinical sciences ,Health sciences - Abstract
BackgroundData on the relations between kidney function abnormalities and stroke in type 2 diabetes are limited. We evaluated the associations of kidney function abnormalities and chronic kidney disease (CKD) stages with incident stroke in a large sample of adults with type 2 diabetes.MethodsParticipants with type 2 diabetes from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study without history of stroke at baseline were included. Urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) were assessed at baseline. CKD categories were defined according to the KDIGO (Kidney Disease: Improving Global Outcomes) guidelines. Cox proportional hazards regression models were used to compute hazard ratios (HR) and 95% confidence intervals (CI) for stroke in relation to measures of kidney function and CKD categories.ResultsA total of 9170 participants (mean age 62.8 [SD: 6.6] years, 38.2% women, 62.9% white) were included. Over a median follow-up of 4.9 years (interquartile range: 4.0-5.7), 156 participants developed a stroke (incidence rate 3.6/1000 person-years [95% CI 3.0-4.2]). After adjusting for relevant confounders, higher UACR and lower eGFR were each associated with increased risk of stroke. Compared to UACR
- Published
- 2022
21. Abstract 9861: Geographic Variation in Prescription of Heart Failure Guideline Directed Medical Therapies for United States Veterans is Prevalent Nationwide
- Author
-
Kosaraju, Revanth, Fonarow, Gregg C, Ong, Michael K, Heidenreich, Paul A, Washington, Donna L, Wang, Xiaoyan, and Ziaeian, Boback
- Subjects
Clinical Research ,Cardiovascular ,Good Health and Well Being ,Cardiorespiratory Medicine and Haematology ,Clinical Sciences ,Public Health and Health Services ,Cardiovascular System & Hematology - Abstract
Introduction: In patients with heart failure with reduced ejection fraction (HFrEF), use of guideline directed medical therapies (GDMT) reduces mortality. Whether there is geographic variation in GDMT prescribing is not well-characterized. Hypothesis: We assessed the hypothesis that there is wide geographic variation nationally within the Veterans Affairs (VA) healthcare system for the receipt of GDMT. Methods: We linked the primary residence address of a cohort of Veterans with HFrEF receiving care at VA facilities (n=178,856) to hospital referral regions (HRRs). Using VA and non-VA pharmacy data between July 1, 2020 and July 1, 2021, we defined receipt of GDMT. For each HRR, we calculated the percentage of eligible Veterans that were prescribed each class of GDMT and a composite GDMT z-score. Lastly, we constructed national choropleth maps to depict HRR geographic variation in composite z-scores and prescription of each class of GDMT. Results: There was significant variation in individual GDMT class prescription and composite score across HRRs as shown in choropleth maps ( Figure) . Within HRRs, beta-blocker prescription was highest, with a median 80% of Veterans (interquartile range [IQR] 77.3% to 82.2%), afterload-reducing agents including angiotensin converting enzyme inhibitor / angiotensin receptor blocker / angiotensin receptor-neprilysin inhibitors (ARNI) 69.3% (IQR 66.4% to 72.1%), mineralocorticoid receptor antagonists (MRA) 29.2% (IQR 25.8% to 33.9%), sodium-glucose cotransporter 2 inhibitors (SGLT2I) 10.3% (IQR 7.7% to 12.8%), and ARNI 12.2% (IQR 8.6% to 15.3%). HRRs with the highest and lowest composite scores were often found in the same U.S. Census Regions. Conclusions: In conclusion, wide geographic disparities are present for GDMT prescribing to Veterans across HRRs. Veteran receipt of ARNI, SGLT2I, and MRA is low nationwide. Targeted approaches may be necessary to improve GDMT prescription for Veterans in lower performing HRRs.
- Published
- 2022
22. Abstract 13840: Impact of Age and Variant on Cardiovascular Events Among Patients Hospitalized With COVID-19: An Analysis From the AHA COVID-19 CVD Registry
- Author
-
Srivastava, Pratyaksh K, Klomhaus, Alexandra M, Tehrani, David M, Ziaeian, Boback, Rafique, Asim, Desai, Pooja S, Fonarow, Gregg C, De Lemos, James A, Parikh, Rushi, and Yang, Eric H
- Subjects
Aging ,Cardiovascular ,Heart Disease ,Good Health and Well Being ,Cardiorespiratory Medicine and Haematology ,Clinical Sciences ,Public Health and Health Services ,Cardiovascular System & Hematology - Abstract
Introduction: The COVID-19 pandemic has caused significant cardiovascular (CV) morbidity and mortality. Using a national registry, we evaluate the impact of age and variant on CV outcomes across the three main coronavirus waves. Methods: Using the AHA’s COVID-19 CV Disease Registry, we divided patients hospitalized with COVID-19 into three groups based on dominant variant at the time of admission (Alpha, Delta, Omicron). We further stratified patients based on age (young: 18-40, older: >40 years). Using adjusted logistic regression, we compared rates of major adverse cardiovascular events (MACE: new onset heart failure, myocardial infarction, stroke, or death) and in-patient mortality between the groups. Results: There were 41,426 patients in the alpha wave (young: 5,585, older: 35,841), 3,349 patients in the delta wave (young: 690, older: 2,659), and 646 patients in the omicron wave (young: 213, older: 433). The cohort’s median (25 th -75 th %ile) age was 63 (50-75) years. 46.8% of the patients were female. Rates of MACE in the Alpha, Delta, and Omicron waves were 20.8%, 23.6%, and 15.5%. Rates of death were 14.0%, 14.8% and 6.0%, respectively. Compared to alpha, patients presenting during delta had increased odds of MACE and death (OR: 1.57 [1.42-1.73] and OR: 1.49 [1.34-1.66]). Patients presenting during omicron had decreased odds of death (OR: 0.6 [0.43-0.84]) and similar odds of MACE compared to alpha. When stratifying by age, both young and older patients presenting during delta had increased odds of MACE and death when compared to alpha (Fig 1A). When compared to young patients, older patients had increased odds of MACE in all three waves (Fig 1B). Conclusions: Patients had increased odds of MACE and death during delta compared to alpha. Compared to young patients, older patients had increased odds of MACE across all three waves. These findings help elucidate the differential impact of age and variant on cardiovascular outcomes among those hospitalized with COVID-19.
- Published
- 2022
23. US Surveillance of Acute Ischemic Stroke Patient Characteristics, Care Quality, and Outcomes for 2019.
- Author
-
Ziaeian, Boback, Xu, Haolin, Matsouaka, Roland A, Xian, Ying, Khan, Yosef, Schwamm, Lee S, Smith, Eric E, and Fonarow, Gregg C
- Subjects
Humans ,Fibrinolytic Agents ,Anticoagulants ,Platelet Aggregation Inhibitors ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,Treatment Outcome ,Bayes Theorem ,Aged ,Quality of Health Care ,United States ,Female ,Male ,Stroke ,Ischemic Stroke ,Bayesian analysis ,epidemiology ,health services ,ischemic stroke ,quality and outcomes ,Prevention ,Health Services ,Clinical Research ,Brain Disorders ,Good Health and Well Being ,Cardiorespiratory Medicine and Haematology ,Clinical Sciences ,Neurosciences ,Neurology & Neurosurgery - Abstract
BackgroundThe United States lacks a timely and accurate nationwide surveillance system for acute ischemic stroke (AIS). We use the Get With The Guidelines-Stroke registry to apply poststratification survey weights to generate national assessment of AIS epidemiology, hospital care quality, and in-hospital outcomes.MethodsClinical data from the Get With The Guidelines-Stroke registry were weighted using a Bayesian interpolation method anchored to observations from the national inpatient sample. To generate a US stroke forecast for 2019, we linearized time trend estimates from the national inpatient sample to project anticipated AIS hospital volume, distribution, and race/ethnicity characteristics for the year 2019. Primary measures of AIS epidemiology and clinical care included patient and hospital characteristics, stroke severity, vital and laboratory measures, treatment interventions, performance measures, disposition, and clinical outcomes at discharge.ResultsWe estimate 552 476 patients with AIS were admitted in 2019 to US hospitals. Median age was 71 (interquartile range, 60-81), 48.8% female. Atrial fibrillation was diagnosed in 22.6%, 30.2% had prior stroke/transient ischemic attack, and 36.4% had diabetes. At baseline, 46.4% of patients with AIS were taking antiplatelet agents, 19.2% anticoagulants, and 46.3% cholesterol-reducers. Mortality was 4.4%, and only 52.3% were able to ambulate independently at discharge. Performance nationally on AIS achievement measures were generally higher than 95% for all measures but the use of thrombolytics within 3 hours of early stroke presentations (81.9%). Additional quality measures had lower rates of receipt: dysphagia screening (84.9%), early thrombolytics by 4.5 hours (79.7%), and statin therapy (80.6%).ConclusionsWe provide timely, reliable, and actionable US national AIS surveillance using Bayesian interpolation poststratification weights. These data may facilitate more targeted quality improvement efforts, resource allocation, and national policies to improve AIS care and outcomes.
- Published
- 2022
24. The need for increased pragmatism in cardiovascular clinical trials
- Author
-
Usman, Muhammad Shariq, Van Spall, Harriette GC, Greene, Stephen J, Pandey, Ambarish, McGuire, Darren K, Ali, Ziad A, Mentz, Robert J, Fonarow, Gregg C, Spertus, John A, Anker, Stefan D, Butler, Javed, James, Stefan K, and Khan, Muhammad Shahzeb
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Comparative Effectiveness Research ,Cardiovascular ,Heart Disease ,Clinical Trials and Supportive Activities ,Prevention ,Clinical Research ,Good Health and Well Being ,Cardiovascular Diseases ,Humans ,Cardiovascular System & Hematology ,Cardiovascular medicine and haematology - Abstract
The majority of cardiovascular randomized controlled trials (RCTs) test interventions in selected patient populations under explicitly protocol-defined settings. Although these 'explanatory' trial designs optimize conditions to test the efficacy and safety of an intervention, they limit the generalizability of trial findings in broader clinical settings. The concept of 'pragmatism' in RCTs addresses this concern by providing counterbalance to the more idealized situation underpinning explanatory RCTs and optimizing effectiveness over efficacy. The central tenets of pragmatism in RCTs are to test interventions in routine clinical settings, with patients who are representative of broad clinical practice, and to reduce the burden on investigators and participants by minimizing the number of trial visits and the intensity of trial-based testing. Pragmatic evaluation of interventions is particularly important in cardiovascular diseases, where the risk of death among patients has remained fairly stable over the past few decades despite the development of new therapeutic interventions. Pragmatic RCTs can help to reveal the 'real-world' effectiveness of therapeutic interventions and elucidate barriers to their implementation. In this Review, we discuss the attributes of pragmatism in RCT design, conduct and interpretation as well as the general need for increased pragmatism in cardiovascular RCTs. We also summarize current challenges and potential solutions to the implementation of pragmatism in RCTs and highlight selected ongoing and completed cardiovascular RCTs with pragmatic trial designs.
- Published
- 2022
25. Twenty Years of Get With The Guidelines-Stroke: Celebrating Past Successes, Lessons Learned, and Future Challenges
- Author
-
Reeves, Mathew J., Fonarow, Gregg C., Smith, Eric E., Sheth, Kevin N., Messe, Steven R., and Schwamm, Lee H.
- Published
- 2024
- Full Text
- View/download PDF
26. Mapping the Ecological Terrain of Stroke Prehospital Delay: A Nationwide Registry Study
- Author
-
Dhand, Amar, Reeves, Mathew J., Mu, Yi, Rosner, Bernard A., Rothfeld-Wehrwein, Zachary R., Nieves, Amber, Dhongade, Vrushali A., Jarman, Molly, Bergmark, Regan W., Semco, Robert S., Ader, Jeremy, Marshall, Brandon D.L., Goedel, William C., Fonarow, Gregg C., Smith, Eric E., Saver, Jeffrey L., Schwamm, Lee H., and Sheth, Kevin N.
- Published
- 2024
- Full Text
- View/download PDF
27. Generalizable Approach to Quantifying Guideline-Directed Medical Therapy
- Author
-
Khan, Mirza S., Chan, Paul S., Sherrod, Charles F., Ikemura, Nobuhiro, Sauer, Andrew J., Jones, Philip G., Fonarow, Gregg C., Butler, Javed, DeVore, Adam D., Lund, Lars H., and Spertus, John A.
- Published
- 2024
- Full Text
- View/download PDF
28. Does the Effectiveness of a Medicine Copay Voucher Vary by Baseline Medication Out‐Of‐Pocket Expenses? Insights From ARTEMIS
- Author
-
Rymer, Jennifer A, Kaltenbach, Lisa A, Peterson, Eric D, Cohen, David J, Fonarow, Gregg C, Choudhry, Niteesh K, Henry, Timothy D, Cannon, Christopher P, and Wang, Tracy Y
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Cost Effectiveness Research ,Heart Disease - Coronary Heart Disease ,Cardiovascular ,Heart Disease ,Good Health and Well Being ,Humans ,Health Expenditures ,Medication Adherence ,Myocardial Infarction ,Purinergic P2Y Receptor Antagonists ,Treatment Outcome ,copay ,myocardial infarction ,persistence ,voucher ,Cardiorespiratory Medicine and Haematology ,Cardiovascular medicine and haematology - Abstract
Background Persistence to P2Y12 inhibitors after myocardial infarction (MI) remains low. Out-of-pocket cost is cited as a factor affecting medication compliance. We examined whether a copayment intervention affected 1-year persistence to P2Y12 inhibitors and clinical outcomes. Methods and Results In an analysis of ARTEMIS (Affordability and Real-World Antiplatelet Treatment Effectiveness After Myocardial Infarction Study), patients with MI discharged on a P2Y12 inhibitor were stratified by baseline out-of-pocket medication burden: low ($0-$49 per month), intermediate ($50-$149 per month), and high (≥$150 per month). The impact of the voucher intervention on 1-year P2Y12 inhibitor persistence was examined using a logistic regression model with generalized estimating equations. We assessed the rates of major adverse cardiovascular events among the groups using a Kaplan-Meier estimator. Among 7351 MI-treated patients at 282 hospitals, 54.2% patients were in the low copay group, 32.0% in the middle copay group, and 13.8% in the high copay group. Patients in higher copay groups were more likely to have a history of prior MI, heart failure, and diabetes compared with the low copay group (all P
- Published
- 2022
29. SGLT2 Inhibitors in Heart Failure: Early Initiation to Achieve Rapid Clinical Benefits.
- Author
-
Dixit, Neal M, Ziaeian, Boback, and Fonarow, Gregg C
- Subjects
Humans ,Diabetes Mellitus ,Type 2 ,Sodium ,Glucose ,Stroke Volume ,Quality of Life ,Heart Failure ,Sodium-Glucose Transporter 2 Inhibitors ,Guideline-directed medical therapy ,Heart failure with preserved ejection fraction ,Heart failure with reduced ejection fraction ,Initiation and sequencing ,Heart Disease ,Cardiovascular ,Good Health and Well Being ,Cardiovascular System & Hematology - Abstract
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a recent addition to the pillars of medical therapy for heart failure (HF) with reduced ejection fraction, all of which improve quality of life, morbidity, and mortality. These benefits are evident within the first 30 days of initiation. This review discusses the rationale for SGLT2i initiation in simultaneous or in rapid sequence with other guideline-directed medical therapy (GDMT). We also discuss SGLT2i use and early benefits in HF patients with an ejection fraction greater than 40%.
- Published
- 2022
30. The design of the Dashboard Activated Services and Telehealth for Heart Failure (DASH-HF) study: A pragmatic quality improvement randomized implementation trial for patients with heart failure with reduced ejection fraction
- Author
-
Verma, Aradhana, Fonarow, Gregg C, Hsu, Jeffrey J, Jackevicius, Cynthia A, Mody, Freny Vaghaiwalla, Amidi, Omid, Goldberg, Sarah, Upparapalli, Deepti, Theodoropoulos, Kleanthis, Gregorio, Stephanie, Chang, Donald S, Bostrom, Kristina, Althouse, Andrew D, and Ziaeian, Boback
- Subjects
Health Services and Systems ,Health Sciences ,Heart Disease ,Clinical Research ,Cardiovascular ,Prevention ,Health Services ,Clinical Trials and Supportive Activities ,Good Health and Well Being ,Heart Failure ,Hospitalization ,Humans ,Quality Improvement ,Stroke Volume ,Telemedicine ,Heart failure ,Guideline -directed medical treatment ,Quality improvement ,Guideline-directed medical treatment ,Medical and Health Sciences ,General Clinical Medicine ,Public Health ,Biomedical and clinical sciences ,Health sciences - Abstract
BackgroundGaps in the receipt and dosing of guideline-directed medical therapy (GDMT) persist for patients with heart failure with reduced ejection fraction (HFrEF) [1]. In 2020, the Veterans Affairs (VA) developed a heart failure (HF) specific population dashboard to monitor care quality and performance on standard HFrEF performance measures [2].MethodsThe Dashboard Activated Services and Telehealth for HF (DASH-HF) study is a pragmatic randomized quality improvement study designed to evaluate the utility of proactive population management clinics using the VA's HF dashboard to optimize GDMT for patients with HFrEF. Panel management telemedicine clinics incorporated multidisciplinary clinicians to perform chart review and impromptu telephone encounters to evaluate current HFrEF management and opportunities to optimize GDMT. The study will evaluate the efficacy of proactive panel management to usual care at 6 months as quantified by the GDMT optimization potential score. Secondary outcomes include hospitalizations, mortality, and clinician time per intervention. The study completed enrollment and randomization of 300 participants. The intervention was performed from September to December 2021.ConclusionDASH-HF will contribute to the literature by evaluating use of the existing VA dashboard to identify HF patients with the lowest adherence to GDMT and proactively target this group for the intervention.Registrationhttps://clinicaltrials.gov/. Unique identifier: NCT05001165.
- Published
- 2022
31. Cardiovascular Safety Reporting in Contemporary Breast Cancer Clinical Trials
- Author
-
Hamid, Arsalan, Anker, Markus S, Ruckdeschel, John C, Khan, Muhammad Shahzeb, Tharwani, Arsal, Oshunbade, Adebamike A, Kipchumba, Rodney K, Thigpen, Samuel C, Anker, Stefan D, Fonarow, Gregg C, Hall, Michael E, and Butler, Javed
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Patient Safety ,Cardiovascular ,Clinical Trials and Supportive Activities ,Cancer ,Clinical Research ,Heart Disease ,Breast Cancer ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Good Health and Well Being ,Breast Neoplasms ,Female ,Humans ,Troponin ,cancer therapy ,cardio-oncology ,cardiovascular disease ,pharmacotherapy ,safety ,cardio‐oncology ,Cardiorespiratory Medicine and Haematology ,Cardiovascular medicine and haematology - Abstract
Background Several cancer therapies have been associated with cardiovascular harm in early-phase clinical trials. However, some cardiovascular harms do not manifest until later-phase trials. To limit interdisease variability, we focused on breast cancer. Thus, we assessed the reporting of cardiovascular safety monitoring and outcomes in phase 2 and 3 contemporary breast cancer clinical trials. Methods and Results We searched Embase and Medline records for phase 2 and 3 breast cancer pharmacotherapy trials. We examined exclusion criterion as a result of cardiovascular conditions, adverse cardiovascular event reporting, and cardiovascular safety assessment through cardiovascular imaging, ECG, troponin, or natriuretic peptides. Fisher's exact test was utilized to compare reporting. Fifty clinical trials were included in our study. Patients were excluded because of cardiovascular conditions in 42 (84%) trials. Heart failure was a frequent exclusion criterion (n=31; 62% trials). Adverse cardiovascular events were reported in 43 (86%) trials. Cardiovascular safety assessments were not reported in 23 (46%) trials, whereas natriuretic peptide and troponin assessments were not reported in any trial. Cardiovascular safety assessments were more frequently reported in industry-funded trials (69.2% versus 0.0%; P
- Published
- 2022
32. Expenditure on Heart Failure in the United States: The Medical Expenditure Panel Survey 2009-2018.
- Author
-
Bhatnagar, Roshni, Fonarow, Gregg C, Heidenreich, Paul A, and Ziaeian, Boback
- Subjects
Humans ,Diabetes Mellitus ,Type 2 ,Ambulatory Care ,Hospitalization ,Adult ,Health Expenditures ,United States ,Heart Failure ,Medical Expenditure Panel Survey ,health care economics ,health expenditure ,heart failure ,Heart Disease ,Clinical Research ,Cardiovascular ,Health Services ,Good Health and Well Being ,  ,Cardiorespiratory Medicine and Haematology - Abstract
BackgroundWith rising United States health care expenditure, estimating current spending for patients with heart failure (HF) informs the value of preventative health interventions.ObjectivesThe purpose of this study was to estimate current health care expenditure growth for patients with HF in the United States.MethodsThe authors pooled MEPS (Medical Expenditure Panel Survey) data from 2009-2018 to calculate total HF-related expenditure across clinical settings in the United States. A 2-part model adjusted for demographics, comorbidities, and year was used to estimate annual mean and incremental expenditures associated with HF.ResultsIn the United States, an average of $28,950 (2018 inflation-adjusted dollars) is spent per year for health care-related expenditure for individuals with HF compared with $5,727 for individuals without HF. After adjusting for demographics and comorbidities, a diagnosis of HF was associated with $3,594 in annual incremental expenditure compared with those without HF. HF-related expenditure increased from $26,864 annual per person in 2009-2010 to $32,955 in 2017-2018, representing a 23% rise over 10 years. In comparison, expenditure on myocardial infarction, type 2 diabetes mellitus, and cancer grew by 16%, 28%, and 16%, respectively. Most of the cost was related to hospitalization: $12,569 per year. Outpatient office-based care and prescription medications saw the greatest growth in cost over the period, 41% and 24%, respectively. Estimated incremental national expenditure for HF per year was $22.3 billion; total annual expenditure for adults with HF was $179.5 billion.ConclusionsHF is a costly condition for which expenditure is growing faster than that of other chronic conditions.
- Published
- 2022
33. Angiotensin Receptor Neprilysin Inhibition and Associated Outcomes by Race and Ethnicity in Patients With Heart Failure With Reduced Ejection Fraction: Data From CHAMP‐HF
- Author
-
Chapman, Brittany, Hellkamp, Anne S, Thomas, Laine E, Albert, Nancy M, Butler, Javed, Patterson, J Herbert, Hernandez, Adrian F, Williams, Fredonia B, Shen, Xian, Spertus, John A, Fonarow, Gregg C, and DeVore, Adam D
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Cardiovascular ,Clinical Research ,Heart Disease ,angiotensin receptor neprilysin inhibitor ,heart failure ,population groups ,registries ,sacubitril/valsartan ,Cardiorespiratory Medicine and Haematology ,Cardiovascular medicine and haematology - Abstract
Background There are limited data on the use of angiotensin receptor neprilysin inhibitors (ARNIs) in minority populations with heart failure (HF) with reduced ejection fraction. We used data from the CHAMP-HF (Change the Management of Patients With Heart Failure) registry to evaluate ARNI initiation and associated changes in health status and clinical outcomes across different races and ethnicities. Methods and Results CHAMP-HF was a prospective, observational registry of US outpatients with chronic HF with reduced ejection fraction. We compared patients starting ARNI with patients not starting ARNI using a propensity-matched analysis. Patients were grouped as Hispanic, non-Hispanic Black, non-Hispanic White, or non-Hispanic other individuals, where "non-Hispanic other" consists of all patients who did not identify as Hispanic, Black, or White. Health status was assessed using the 12-item Kansas City Cardiomyopathy Questionnaire. Outcomes were analyzed with multivariable models that included race and ethnicity, ARNI initiation, and an interaction term between race and ethnicity and ARNI initiation. Cox proportional hazards models were used for death/HF hospitalization, and multiple regression was used for change in Kansas City Cardiomyopathy Questionnaire score. The analysis included 1516 patients, with 758 patients in each group (ARNI and no ARNI). Changes in Kansas City Cardiomyopathy Questionnaire score after ARNI initiation were similar among all race and ethnicity groups (mean [SD], non-Hispanic White individuals, 3.5 [19.0]; non-Hispanic Black individuals, 2.0 [17.0]; non-Hispanic other individuals, 5.5 [20.3]; and Hispanic individuals, 3.2 [20.1]), with no statistically significant interaction between race and ethnicity and ARNI initiation (P=0.21). There was similarly no statistically significant interaction between race and ethnicity and ARNI initiation for HF hospitalization (P=0.82) or all-cause mortality (P=0.92). Conclusions In a large registry of outpatients with HF with reduced ejection fraction, the association between ARNI initiation and outcomes did not differ by race and ethnicity. These data support the use of ARNI therapy for chronic HF with reduced ejection fraction irrespective of race and ethnicity.
- Published
- 2022
34. Heart failure quality of care and in‐hospital outcomes during the COVID‐19 pandemic: findings from the Get With The Guidelines‐Heart Failure registry
- Author
-
Keshvani, Neil, Mehta, Anurag, Alger, Heather M, Rutan, Christine, Williams, Joseph, Zhang, Shuiaqi, Young, Rebecca, Alhanti, Brooke, Chiswell, Karen, Greene, Stephen J, DeVore, Adam D, Yancy, Clyde W, Fonarow, Gregg C, and Pandey, Ambarish
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Heart Disease ,Cardiovascular ,Clinical Research ,Patient Safety ,8.1 Organisation and delivery of services ,Health and social care services research ,Good Health and Well Being ,Aged ,COVID-19 ,Female ,Heart Failure ,Hospitalization ,Hospitals ,Humans ,Male ,Pandemics ,Quality of Health Care ,Registries ,United States ,Heart failure ,Quality of care ,Outcomes ,Cardiorespiratory Medicine and Haematology ,Cardiovascular System & Hematology ,Cardiovascular medicine and haematology - Abstract
AimsTo assess heart failure (HF) in-hospital quality of care and outcomes before and during the COVID-19 pandemic.Methods and resultsPatients hospitalized for HF with ejection fraction (EF)
- Published
- 2022
35. Cost-Effectiveness of Medical Therapy for Heart Failure With Mildly Reduced and Preserved Ejection Fraction
- Author
-
Dixit, Neal M., Truong, Katie P., Vaduganathan, Muthiah, Ziaeian, Boback, and Fonarow, Gregg C.
- Published
- 2024
- Full Text
- View/download PDF
36. Characteristics of High-Performing Hospitals in Cardiogenic Shock Following Acute Myocardial Infarction
- Author
-
Saha, Amit, Li, Shuang, de Lemos, James A., Pandey, Ambarish, Bhatt, Deepak L., Fonarow, Gregg C., Nallamothu, Brahmajee K., Wang, Tracy Y., Navar, Ann Marie, Peterson, Eric, Matsouaka, Roland A., Bavry, Anthony A., Das, Sandeep R., Grodin, Justin L., Khera, Rohan, Drazner, Mark H., and Kumbhani, Dharam J.
- Published
- 2024
- Full Text
- View/download PDF
37. Racial and ethnic disparities in cardiovascular disease - analysis across major US national databases
- Author
-
Minhas, Abdul Mannan Khan, Talha, Khawaja M., Abramov, Dmitry, Johnson, Heather M., Antoine, Steve, Rodriguez, Fatima, Fudim, Marat, Michos, Erin D., Misra, Arunima, Abushamat, Layla, Nambi, Vijay, Fonarow, Gregg C., Ballantyne, Christie M., and Virani, Salim S.
- Published
- 2024
- Full Text
- View/download PDF
38. Patterns, Prognostic Implications, and Rural-Urban Disparities in Optimal GDMT Following HFrEF Diagnosis Among Medicare Beneficiaries
- Author
-
Mentias, Amgad, Keshvani, Neil, Sumarsono, Andrew, Desai, Rohan, Khan, Muhammad Shahzeb, Menon, Venu, Hsich, Eileen, Bress, Adam P., Jacobs, Joshua, Vasan, Ramachandran S., Fonarow, Gregg C., and Pandey, Ambarish
- Published
- 2024
- Full Text
- View/download PDF
39. Time to benefit of colchicine in patients with cardiovascular disease: A pooled analysis of randomized controlled trials
- Author
-
Sun, Haonan, Huang, Chuanyi, Li, Linjie, Zhu, Wenjun, Li, Jingge, Sun, Pengfei, A, Geru, Fonarow, Gregg C., Yang, Qing, and Zhou, Xin
- Published
- 2024
- Full Text
- View/download PDF
40. Prognostic implications of heart failure stages among Chinese community populations: insight from a nationwide population-based study
- Author
-
Zheng, Congyi, Cai, Anping, Wang, Xin, Qiu, Jiayuan, Song, Qingjie, Gu, Runqing, Cao, Xue, Tian, Yixin, Hu, Zhen, Fonarow, Gregg C., Lip, Gregory Y.H., Wang, Zengwu, and Feng, Yingqing
- Published
- 2024
- Full Text
- View/download PDF
41. Access to Mobile Health Interventions Among Patients Hospitalized With Heart Failure: Insights Into the Digital Divide From the CONNECT-HF mHealth Substudy
- Author
-
Diamond, Jamie E., Kaltenbach, Lisa A., Granger, Bradi B., Fonarow, Gregg C., Al-Khalidi, Hussein R., Albert, Nancy M., Butler, Javed, Allen, Larry A., Lanfear, David E., Thibodeau, Jennifer T., Granger, Christopher B., Hernandez, Adrian F., Ariely, Dan, and DeVore, Adam D.
- Published
- 2024
- Full Text
- View/download PDF
42. Global Benefit of SGLT2 Inhibitors in Heart Failure With Reduced Ejection Fraction ∗
- Author
-
Brownell, Nicholas K, Ziaeian, Boback, and Fonarow, Gregg C
- Subjects
Information and Computing Sciences ,Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Asia ,SGLT2 inhibitor ,ejection fraction ,heart failure - Published
- 2022
43. Cardiac autonomic neuropathy and risk of incident heart failure among adults with type 2 diabetes
- Author
-
Kaze, Arnaud D, Yuyun, Matthew F, Erqou, Sebhat, Fonarow, Gregg C, and Echouffo‐Tcheugui, Justin B
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Clinical Research ,Cardiovascular ,Diabetes ,Prevention ,Heart Disease ,Metabolic and endocrine ,Adult ,Autonomic Nervous System ,Diabetes Mellitus ,Type 2 ,Female ,Heart ,Heart Failure ,Heart Rate ,Humans ,Male ,Middle Aged ,Cardiac autonomic neuropathy ,Heart failure ,Risk ,Type 2 diabetes ,Cardiorespiratory Medicine and Haematology ,Cardiovascular System & Hematology ,Cardiovascular medicine and haematology - Abstract
AimsCommunity-based data on the association between cardiac autonomic neuropathy (CAN) and incident heart failure (HF) in type 2 diabetes are limited. We evaluated the association of CAN with incident HF in adults with type 2 diabetes.Methods and resultsThis analysis included participants from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study without HF at baseline. CAN was assessed by electrocardiogram-based measures of heart rate variability (HRV) and QT interval index (QTI). HRV was measured using standard deviation of all normal-to-normal intervals (SDNN) and root mean square of successive differences between normal-to-normal intervals (rMSSD). CAN was defined using composite measures of the lowest quartile of SDNN and highest quartiles of QTI and heart rate. Multivariable Cox regression models were used to generate adjusted hazard ratios (aHR) for HF in relation to various CAN measures. A total of 7160 participants (mean age 62.3 [standard deviation 6.4] years, 40.8% women, 61.9% white) were included. Over a median follow-up of 4.9 years (interquartile range 4.0-5.7), 222 participants developed incident HF. After multivariable adjustment for relevant confounders, lower HRV as assessed by SDNN was associated with a higher risk of HF (aHR for the lowest vs highest quartile of SDNN: 1.70, 95% confidence interval [CI] 1.14-2.54). Participants with CAN (defined as lowest quartile of SDNN and highest quartiles of QTI and heart rate) had a 2.7-fold greater risk of HF (aHR 2.65, 95% CI 1.57-4.48).ConclusionsIn a large cohort of adults with type 2 diabetes, CAN was independently associated with higher risk of incident HF.
- Published
- 2022
44. Robustness of outcomes in trials evaluating sodium–glucose co‐transporter 2 inhibitors for heart failure
- Author
-
Usman, Muhammad Shariq, Khan, Muhammad Shahzeb, Fonarow, Gregg C, Greene, Stephen J, Friede, Tim, Vaduganathan, Muthiah, Filippatos, Gerasimos, Coats, Andrew J Stewart, Anker, Stefan D, and Butler, Javed
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Cardiovascular ,Heart Disease ,Good Health and Well Being ,Glucose ,Heart Failure ,Humans ,Sodium ,Sodium-Glucose Transporter 2 Inhibitors ,Symporters ,Fragility index ,Robustness ,Sodium-glucose co-transporter 2 inhibitors ,Cardiac failure ,Cardiorespiratory Medicine and Haematology ,Cardiovascular medicine and haematology - Abstract
AimsRecent trials have evaluated sodium-glucose co-transporter 2 inhibitors in patients with heart failure (HF). We sought to assess the robustness of findings from these trials using the fragility index (FI).Methods and resultsFragility index is defined as the minimum number of patients that must be moved from the 'non-event' to the 'event' group to turn a statistically significant result to non-significant. In addition to FI, fragility quotient [(FQ); FI divided by the sample size] was calculated to assess the proportion of events that must be moved to change the significance. For statistically non-significant outcomes, reverse fragility index (RFI) and reverse fragility quotient (RFQ) were calculated. Robustness of findings after pooling data from all three trials was also assessed. A robust reduction in first HF hospitalization or cardiovascular mortality was seen with dapagliflozin (FI = 62 and FQ = 0.013), empagliflozin (FI = 50 and FQ = 0.013), and sotagliflozin (FI = 60 and FQ = 0.049). Dapagliflozin nominally improved all-cause and cardiovascular mortality, with modest FI (n = 8 and 5) and FQ (0.002 and 0.001). Empagliflozin and sotagliflozin did not demonstrate statistically significant reductions in all-cause mortality, with modest RFI (empagliflozin: RFI = 26 and RFQ = 0.007; sotagliflozin: RFI = 6 and RFQ = 0.005). A similar trend was seen with cardiovascular mortality (empagliflozin: RFI = 24 and RFQ = 0.006; sotagliflozin: RFI = 7 and RFQ = 0.006). Upon meta-analysis, the result for first HF hospitalization or cardiovascular mortality was robust (FI = 95 and FQ = 0.010). The reductions in all-cause (FI = 12 and FQ = 0.001) and cardiovascular mortality (FI = 9 and FQ = 0.001), while statistically significant, were fragile.ConclusionImprovement in the composite outcome of first HF hospitalization or cardiovascular death was highly concordant and robust across sodium-glucose co-transporter 2 inhibitor trials. In contrast, secondary endpoints of all-cause and cardiovascular mortality were statistically fragile, underscoring the need to power trials for mortality to fully understand the benefit of therapies on fatal events.
- Published
- 2022
45. Temporal Trends in Racial and Ethnic Disparities in Endovascular Therapy in Acute Ischemic Stroke
- Author
-
Sheriff, Faheem, Xu, Haolin, Maud, Alberto, Gupta, Vikas, Vellipuram, Anantha, Fonarow, Gregg C, Matsouaka, Roland A, Xian, Ying, Reeves, Mathew, Smith, Eric E, Saver, Jeffrey, Rodriguez, Gustavo, Cruz‐Flores, Salvador, and Schwamm, Lee H
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Brain Disorders ,Stroke ,Clinical Research ,Good Health and Well Being ,Endovascular Procedures ,Ethnicity ,Hispanic or Latino ,Humans ,Ischemic Stroke ,Treatment Outcome ,endovascular therapy ,health equity ,ischemic stroke ,race and ethnicity ,Cardiorespiratory Medicine and Haematology ,Cardiovascular medicine and haematology - Abstract
Introduction Endovascular therapy (EVT) use increased following clinical trials publication in 2015, but limited data suggest there may be persistent race and ethnicity differences. Methods and Results We included all patients with acute ischemic stroke arriving within 6 hours of last known well and with National Institute of Health Stroke Scale (NIHSS) score ≥6 between April 2012 and June 2019 in the Get With The Guidelines-Stroke database and evaluated the association between race and ethnicity and EVT use and outcomes, comparing the era before versus after 2015. Of 302 965 potentially eligible patients; 42 422 (14%) underwent EVT. Although EVT use increased over time in all racial and ethnic groups, Black patients had reduced odds of EVT use compared with non-Hispanic White (NHW) patients (adjusted odds ratio [aOR] before 2015, 0.68 [0.58‒0.78]; aOR after 2015, 0.83 [0.76‒0.90]). In-hospital mortality/discharge to hospice was less frequent in Black, Hispanic, and Asian patients compared with NHW. Conversely discharge home was more frequent in Hispanic (29.7%; aOR, 1.28 [1.16‒1.42]), Asian (28.2%; aOR, 1.23 [1.05‒1.44]), and Black (29.1%; aOR, 1.08 [1.00‒1.18]) patients compared with NHW (24%). However, at 3 months, functional independence (modified Rankin Scale, 0-2) occurred less frequently in Black (37.5%; aOR, 0.84 [0.75‒0.95]) and Asian (33%; aOR, 0.79 [0.65‒0.98]) patients compared with NHW patients (38.1%). Conclusions In a large cohort of patients treated with EVT, Black versus NHW patient disparities in EVT use have narrowed over time but still exist. Discharge related outcomes were slightly more favorable in racial and ethnic underrepresented groups; 3-month functional outcomes were worse but improved across all groups with time.
- Published
- 2022
46. Economic Issues in Heart Failure in the United States
- Author
-
Heidenreich, Paul A, Fonarow, Gregg C, Opsha, Yekaterina, Sandhu, Alexander T, Sweitzer, Nancy K, Warraich, Haider J, Chair, HFSA Scientific Statement Committee Members, Butler, Javed, Hsich, Eileen, Pressler, Susan Bennett, Shah, Kevin, Taylor, Kenneth, Sabe, Marwa, and Ng, Tien
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Clinical Sciences ,Clinical Research ,Clinical Trials and Supportive Activities ,Heart Disease - Coronary Heart Disease ,Comparative Effectiveness Research ,Heart Disease ,Health Services ,Cost Effectiveness Research ,Cardiovascular ,5.1 Pharmaceuticals ,8.2 Health and welfare economics ,Health and social care services research ,Development of treatments and therapeutic interventions ,Good Health and Well Being ,Adrenergic beta-Antagonists ,Angiotensin Receptor Antagonists ,Angiotensin-Converting Enzyme Inhibitors ,Cost-Benefit Analysis ,Heart Failure ,Hospitalization ,Humans ,Mineralocorticoid Receptor Antagonists ,United States ,HFSA Scientific Statement Committee Members Chair ,Cardiorespiratory Medicine and Haematology ,Nursing ,Cardiovascular System & Hematology ,Cardiovascular medicine and haematology ,Clinical sciences - Abstract
The cost of heart failure care is high owing to the cost of hospitalization and chronic treatments. Heart failure treatments vary in their benefit and cost. The cost effectiveness of therapies can be determined by comparing the cost of treatment required to obtain a certain benefit, often defined as an increase in 1 year of life. This review was sponsored by the Heart Failure Society of America and describes the growing economic burden of heart failure for patients and the health care system in the United States. It also provides a summary of the cost effectiveness of drugs, devices, diagnostic tests, hospital care, and transitions of care for patients with heart failure. Many medications that are no longer under patent are inexpensive and highly cost-effective. These include angiotensin-converting enzyme inhibitors, beta-blockers and mineralocorticoid receptor antagonists. In contrast, more recently developed medications and devices, vary in cost effectiveness, and often have high out-of-pocket costs for patients.
- Published
- 2022
47. Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction
- Author
-
Tomasoni, Daniela, Fonarow, Gregg C, Adamo, Marianna, Anker, Stefan D, Butler, Javed, Coats, Andrew JS, Filippatos, Gerasimos, Greene, Stephen J, McDonagh, Theresa A, Ponikowski, Piotr, Rosano, Giuseppe, Seferovic, Petar, Vaduganathan, Muthiah, Voors, Adriaan A, and Metra, Marco
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Patient Safety ,Diabetes ,Cardiovascular ,Heart Disease ,Clinical Research ,5.1 Pharmaceuticals ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Development of treatments and therapeutic interventions ,Metabolic and endocrine ,Good Health and Well Being ,Diabetes Mellitus ,Type 2 ,Glucose ,Heart Failure ,Humans ,Quality of Life ,Sodium ,Sodium-Glucose Transporter 2 Inhibitors ,Stroke Volume ,Symporters ,Heart failure with reduced ejection fraction ,Sodium-glucose co-transporter 2 inhibitors ,Dapagliflozin ,Empagliflozin ,Sotagliflozin ,Medical therapy ,Cardiorespiratory Medicine and Haematology ,Cardiovascular System & Hematology ,Cardiovascular medicine and haematology - Abstract
Sodium-glucose co-transporter 2 (SGLT2) inhibitors have recently been recommended as a foundational therapy for patients with heart failure (HF) and reduced ejection fraction (HFrEF) because of their favourable effects on mortality, clinical events and quality of life. While clinical practice guidelines have recommended dapagliflozin or empagliflozin in all patients with HFrEF, or sotagliflozin in those with HFrEF and concomitant diabetes, the timing and practical integration of these drugs in clinical practice is less well defined. We propose that these drugs are candidates for early, upfront administration to patients with newly diagnosed HFrEF and for patients hospitalized with HF. Growing evidence has established early benefits, with clinically meaningful reductions in clinical events that reach statistical significance within days to weeks, following dapagliflozin, empagliflozin or, in diabetic patients, sotagliflozin initiation. Secondly, although major clinical trials have tested these drugs in patients already receiving background HF therapy, secondary analyses showed that their efficacy is independent of that. Third, SGLT2 inhibitors are generally safe and well tolerated, with clinical trial data reporting minimal effects on blood pressure, glycaemia-related adverse events, and no excess in acute kidney injury. Rather, they exert renal protective effects and reduce risk of hyperkalaemia, properties that favour initiation, tolerance and persistence of renin-angiotensin system inhibitors and mineralocorticoid receptor antagonists. This review supports the early initiation of dapagliflozin and empagliflozin (or sotagliflozin limited to patients with diabetes) to rapidly improve clinical outcome and quality of life of HFrEF patients.
- Published
- 2022
48. Seasonal Variation of Atrial Fibrillation Admission and Quality of Care in the United States
- Author
-
Sheehy, Shanshan, Fonarow, Gregg C, Holmes, DaJuanicia N, Lewis, William R, Matsouaka, Roland A, Piccini, Jonathan P, Zhi, Lillian, and Bhatt, Deepak L
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Clinical Research ,Cardiovascular ,Heart Disease ,Atrial Fibrillation ,Hospitalization ,Humans ,Quality Improvement ,Registries ,Seasons ,United States ,atrial fibrillation ,quality of care ,season ,Cardiorespiratory Medicine and Haematology ,Cardiovascular medicine and haematology - Abstract
Background Currently, little is known regarding seasonal variation for atrial fibrillation (AF) in the United States and whether quality of care for AF varies between seasons. Methods and Results The GWTG-AFib (Get With The Guidelines-AFib) registry was initiated by the American Heart Association to enhance national guideline adherence for treatment and management of AF. Our analyses included 61 291 patients who were admitted at 141 participating hospitals from 2014 to 2018 across the United States. Outcomes included numbers of AF admissions and quality-of-care measures (defect-free care, defined as a patient's receiving all eligible measures). For quality-of-care measures, generalized estimating equations accounting for within-site correlations were used to estimate odds ratios (ORs) with 95% CIs, adjusting patient and hospital characteristics. The proportion of AF admissions for each season was similar, with the highest percentage of AF admissions being observed in the fall (spring 25%, summer 25%, fall 27%, and winter 24%). Overall, AF admissions across seasons were similar, with no seasonal variation observed. No seasonal variation was observed for incident AF. There were no seasonal differences in care quality (multivariable adjusted ORs and 95% CIs were 0.93 (0.87-1.00) for winter, 1.09 (1.01-1.18) for summer, and 1.08 (0.97-1.20) for fall, compared with spring). Conclusions In a nationwide quality improvement registry, no seasonal variation was observed in hospital admissions for AF or quality of care for AF.
- Published
- 2022
49. Is the affordable care act medicaid expansion associated with receipt of heart failure guideline-directed medical therapy by race and ethnicity?
- Author
-
Breathett, Khadijah K, Xu, Haolin, Sweitzer, Nancy K, Calhoun, Elizabeth, Matsouaka, Roland A, Yancy, Clyde W, Fonarow, Gregg C, DeVore, Adam D, Bhatt, Deepak L, and Peterson, Pamela N
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Brain Disorders ,Clinical Research ,Cardiovascular ,Heart Disease ,Good Health and Well Being ,Angiotensin Receptor Antagonists ,Angiotensin-Converting Enzyme Inhibitors ,Ethnicity ,Heart Failure ,Humans ,Insurance Coverage ,Medicaid ,Patient Protection and Affordable Care Act ,United States ,evidence-based medicine ,health policy ,heart failure ,hospitalization ,Cardiorespiratory Medicine and Haematology ,Public Health and Health Services ,Cardiovascular System & Hematology ,Cardiovascular medicine and haematology - Abstract
BackgroundUninsurance is a known contributor to racial/ethnic health inequities. Insurance is often needed for prescriptions and follow-up appointments. Therefore, we determined whether the Affordable Care Act(ACA) Medicaid Expansion was associated with increased receipt of guideline-directed medical treatment(GDMT) at discharge among patients hospitalized with heart failure(HF) by race/ethnicity.MethodsUsing Get With The Guidelines-HF registry, logistic regression was used to assess odds of receiving GDMT(HF medications; education; follow-up appointment) in early vs non-adopter states before(2012 - 2013) and after ACA Medicaid Expansion(2014 - 2019) within each race/ethnicity, accounting for patient-level covariates and within-hospital clustering. We tested for an interaction(p-int) between GDMT and pre/post Medicaid Expansion time periods.ResultsAmong 271,606 patients(57.5% early adopter, 42.5% non-adopter), 65.5% were White, 22.8% African American, 8.9% Hispanic, and 2.9% Asian race/ethnicity. Independent of ACA timing, Hispanic patients were more likely to receive all GDMT for residing in early adopter states compared to non-adopter states (P
- Published
- 2022
50. Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials JACC Review Topic of the Week
- Author
-
Fiuzat, Mona, Hamo, Carine E, Butler, Javed, Abraham, William T, DeFilippis, Ersilia M, Fonarow, Gregg C, Lindenfeld, Joann, Mentz, Robert J, Psotka, Mitchell A, Solomon, Scott D, Teerlink, John R, Vaduganathan, Muthiah, Vardeny, Orly, McMurray, John JV, and O’Connor, Christopher M
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Research ,Heart Disease ,Cardiovascular ,Clinical Trials and Supportive Activities ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Cardiovascular Agents ,Clinical Trials as Topic ,Heart Failure ,Humans ,Periodicals as Topic ,Stroke Volume ,clinical trials ,device therapy ,drug therapy ,FDA ,guideline directed ,medical therapy ,heart failure ,HFrEF ,medication ,guideline directed medical therapy ,Cardiorespiratory Medicine and Haematology ,Public Health and Health Services ,Cardiovascular System & Hematology ,Cardiovascular medicine and haematology - Abstract
With the current landscape of approved therapies for heart failure (HF), there is a need to determine the role of a standard background therapy against which novel therapies are studied. The Heart Failure Collaboratory convened a multistakeholder group of clinical investigators, clinicians, patients, government representatives including U.S. Food and Drug Administration and National Institutes of Health participants, payers, and industry in March 2021 to discuss whether standardization of background drug therapy is necessary in clinical trials in patients with HF. The current paper summarizes the discussion and provides potential conceptual approaches, with a focus on therapies indicated for HF with reduced ejection fraction.
- Published
- 2022
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.